TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

Christian Taverna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.